Alto Neuroscience, Inc. (ANRO): Cash & Equivalents
$176.48M
As of 2025-12-31
$243.73M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $176.48M | +4.9% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $168.23M | +103.8% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $82.55M | n/a | 2025-03-20, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $176.48M | +4.9% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $34.33M | -48.5% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $79.38M | +38.6% |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $179.97M | +84.1% |
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $38.92M | -31.1% |
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $18.91M | -44.5% |
| PepGen Inc. (PEPG) | 2025-12-31 | $60.51M | +22.4% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $37.73M | -18.1% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $80.88M | +45.8% |
Compare ANRO, LXRX, FBIO, BNTC side by side · Screen every company in Pharmaceutical Preparations ↗